Annals of Surgical Oncology, Vol 2, Issue 1 71-76, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Effect of glutamine on tumor and host growth

D. L. Bartlett, S. Charland and M. H. Torosian
Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia.

BACKGROUND: Oral glutamine supplementation has been found to support gastrointestinal mucosal growth and increase intestinal and systemic toxicity after chemotherapy and radiation therapy. Glutamine is also an important nutrient for rapidly proliferating tumor cells. However, it is not clear whether long-term glutamine supplementation in the tumor-bearing host has a selective benefit for host growth or tumor cell proliferation. METHODS: To study the effect of glutamine in tumor-bearing animals, 30 Lewis/Wistar rats with subcutaneous mammary tumor implants (MAC-33) were randomized to receive a 3% glutamine- or 3% glycerine-enriched (control) diet for 25 days. RESULTS: No significant difference was found in carcass weight, primary tumor weight, or spontaneous pulmonary metastasis with glutamine supplementation. Tumor cell cycle kinetics (aneuploidy, %S and %S [synthetic] + G2/M [growth fraction]) were similar between glutamine-supplemented and control animals. A trophic effect of glutamine on distal ileal mucosa was seen with increased DNA content (344 +/- 68 vs. 184 +/- 38 micrograms/100 mg tissue) (p < 0.05) and RNA content (435 +/- 44 vs. 335 +/- 30 micrograms/100 mg tissue) (p = 0.06) compared with control animals. No detectable differences were observed in liver or muscle, or in tumor DNA, RNA, or protein content. CONCLUSIONS: These findings confirm the trophic effect of glutamine on small intestinal mucosa and suggest that glutamine can be administered to the tumor-bearing host over a long period of time without significantly stimulating tumor growth kinetics or metastasis.

This article has been cited by other articles:

				W.-S. Wang, J.-K. Lin, T.-C. Lin, W.-S. Chen, J.-K. Jiang, H.-S. Wang, T.-J. Chiou, J.-H. Liu, C.-C. Yen, and P.-M. Chen Oral Glutamine Is Effective for Preventing Oxaliplatin-Induced Neuropathy in Colorectal Cancer Patients Oncologist, March 1, 2007; 12(3): 312 - 319. [Abstract] [Full Text] [PDF]

				H. A. Choudry, W. W. Souba, C. Lin, Q. Meng, A. M. Karinch, J. Huang, and M. Pan Stimulation of Expression of the Intestinal Glutamine Transporter ATB0 in Tumor-Bearing Rats Ann. Surg. Oncol., December 1, 2006; 13(12): 1747 - 1753. [Abstract] [Full Text] [PDF]

				J. Glew and C. Sullivan Nutrition Integr Cancer Ther, June 1, 2006; 5(2): 135 - 140. [PDF]

				A. L Buchman Glutamine: commercially essential or conditionally essential? A critical appraisal of the human data Am. J. Clinical Nutrition, July 1, 2001; 74(1): 25 - 32. [Abstract] [Full Text] [PDF]

				L. Vahdat, K. Papadopoulos, D. Lange, S. Leuin, E. Kaufman, D. Donovan, D. Frederick, E. Bagiella, A. Tiersten, G. Nichols, et al. Reduction of Paclitaxel-induced Peripheral Neuropathy with Glutamine Clin. Cancer Res., May 1, 2001; 7(5): 1192 - 1197. [Abstract] [Full Text]